Abstract
We tested the possibility that simvastatin, a competitive inhibitor of HMG-CoA reductase related to mevinolin, might alter cholesterol saturation of gallbladder bile. Ten patients with Type IIa or IIb hypercholesterolemia underwent bile sampling before, and again after, treatment with 20 or 40 mg per day simvastatin for 7 to 13 weeks. Mean cholesterol saturation index of gallbladder bile fell from 1.01 to 0.77 during simvastatin treatment (p less than 0.01). This finding strongly suggests that treatment with HMG-CoA reductase inhibitors will not predispose to development of cholesterol gallstones. Indeed, it raises the possibility that such inhibitors might have a future role to play in treatment of gallstones.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adult
-
Aged
-
Anticholesteremic Agents / therapeutic use*
-
Bile / analysis
-
Bile / drug effects*
-
Bile / metabolism
-
Cholesterol / metabolism*
-
Clinical Trials as Topic
-
Gallbladder / drug effects*
-
Gallbladder / metabolism
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
-
Hypercholesterolemia / drug therapy
-
Hypercholesterolemia / metabolism
-
Lipids / analysis
-
Lovastatin / analogs & derivatives*
-
Lovastatin / therapeutic use
-
Male
-
Middle Aged
-
Random Allocation
-
Simvastatin
-
Time Factors
Substances
-
Anticholesteremic Agents
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Lipids
-
Cholesterol
-
Lovastatin
-
Simvastatin